Skip to content
Head to head

IDEAYA Biosciences vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: IDYA · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

IDYA -23.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
IDYAVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price25.56515.02
Change today-2.33%-1.08%
1-year return-22.9%+22.0%
Market cap$2.47B$130.58B
52-week range25.46 – 42.68412.27 – 568.67
Valuation
P/E (TTM)-5.6833.14
P/E percentile, own 5-yr range83rd99th
P/B2.266.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-1.2815.32
Net profit (TTM)$-123.77M$3.88B
Revenue (TTM)$36.54M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)-95.1%+11.8%
Gross margin--85.5%
Operating margin-1267.3%33.1%
Net margin-1149.6%30.7%
Free cash flow (TTM)$-349.80M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership107.1%96.8%
Insider activity (12mo)42 buy / 6 sell28 buy / 22 sell
Short interest (% of float)8.5%1.9%
Analyst consensus100% buy (11)95% buy / 5% hold (21)
Analyst price target$53 (+107%)$624 (+21%)
StockVane view
StockVane Quant RatingD (18)C (68)
Company
Employees1456,400
Founded20151989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.